Home

TC BioPharm (Holdings) plc - Warrants (TCBPW)

0.0120
+0.0010 (9.09%)
SummaryNewsPress ReleasesChartHistorical
TC BioPharm Doses First 3 Patients in Phase 2b Clinical Trial of Lead Compound, OmnImmune®, To Treat Acute Myeloid Leukemiabenzinga.com
TC Biopharm (NASDAQTCBP) NASDAQ: TCBPWNASDAQTCBPW)
Via Benzinga · November 22, 2022